M. A. Anisimov

M. A. Anisimov

Auto-generated profile, based on publicly available information

M. A. Anisimov

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2021 in Annals of Critical Care
Verified
Journal Article
Open access
IZIgor B. Zabolotskikh
Igor B. Zabolotskikh
MAM. A. Anisimov
M. A. Anisimov
EGE. S. Gorobets
E. S. Gorobets
AGA. I. Gritsan
A. I. Gritsan
KLK. M. Lebedinskii
K. M. Lebedinskii
SES. L. Epstein
S. L. Epstein
According to the latest estimates of the World Health Organization, more than 1 billion people in the world are overweight. In economically developed countries, the proportion of the population with overweight reaches almost 50 %, of which 30 % are obese. In Russia, on average, 30 % of people of working age are obese and 25 % are overweight. Despite the significant economic costs for the prevention and treatment of obesity, mortality at the age of 20–35 with morbid obesity exceeds the average statistical 12 times, mainly from cardiovascular complications. The guidelines provides principles of perioperative management of patients with obesity.

25 March 2024 in MD-Onco
Verified
Journal Article
Open access
PDF file
VGV. E. Gruzdev
V. E. Gruzdev
MAM. A. Anisimov
M. A. Anisimov
YRYu. E. Ryabukhina
Yu. E. Ryabukhina
AOA. V. Oskolkov
A. V. Oskolkov
PZP. A. Zeynalova
P. A. Zeynalova
ЮРЮ. Е. Рябухина
Ю. Е. Рябухина
Therapy of chronic pain syndrome and adequate perioperative pain management during treatment of malignant neoplasms are important problems at the current stage of clinical medicine development. Currently, multimodal pain management is effectively applied through drugs of various pharmacological groups prescribed depending on pain intensity in accordance with a digital rating scale. Associated adverse events as well as impossibility of using peroral or transdermal forms in some cases, limit the use of opioid analgesics. High bioavailability and fast absorption of μ1-opioid receptor agonist tafalgin shown during preclinical studies, relatively favorable safety profile allowed to use this drug in oncological clinic.An experience of using tafalgin in treatment of pain syndrome in patients with malignant tumors at the “Lapino” clinical hospital since 2022 is presented. The effectiveness of the drug is evaluated, and its niche in multimodal pain management is determined.

2 November 2018 in Siberian journal of oncology
Verified
Journal Article
Open access
PDF file
IDI. A. Dadyev
I. A. Dadyev
МDМ. M. Davydov
М. M. Davydov
ACA. K. Chekini
A. K. Chekini
MAM. A. Anisimov
M. A. Anisimov
SASergey G. Afanasyev
Sergey G. Afanasyev
MKM. R. Kanzapetov
M. R. Kanzapetov
Over the past few years, significant advances in surgical and anesthetic techniques as well as appropriate selection of patients have led to an improvement in the immediate and long-term treatment outcomes in patients with non-small cell lung cancer with involvement of tracheal bifurcation. In accordance with the current selection criteria, patients with contralateral lymph node metastases (lung root, aortic window, paratracheal area) require chemotherapy or chemoradiotherapy with subsequent estimation of follow-up and treatment strategy. Surgeries with resection of tracheobronchial bifurcation are considered technically complicated, and they should be performed in carefully selected lung cancer patients and only in specialized centers with extensive experience. It allows the incidence of intra-and postoperative complications to be significantly reduced.

4 March 2022 in MD-Onco
Verified
Journal Article
Open access
PDF file
VGV. E. Gruzdev
V. E. Gruzdev
MAM. A. Anisimov
M. A. Anisimov
In current conditions, increased life expectancy led to increased cancer morbidity. Presence of pain syndrome with significant intensity caused development of numerous guidelines on its treatment. Currently, pain management is based on the stepwise multimodal approach of the World Health Organization. In our opinion, wide application of narcotic analgesics is a disadvantage of this method. This pharmaceutical group has a significant number of adverse effects including addiction, development of hyperalgesia, and potential effect of increased rate of cancer recurrence.The study objective is to optimize the stepwise approach by addition of continuous multimodal analgesia. We aim to develop the principles of complex approach to pain management including new combinations of pharmaceuticals of different modalities and new techniques of continuous safe administration using innovative devices.The article presents a prospective description of a series of clinical cases in which new combinations of pharmaceuticals were administered in the context of complex treatment of pain syndrome of significant intensity. Objective evaluation of pain syndrome was performed using the Numeric Rating Scale.Multimodal intravenous pain management using mobile devices administering a mixture of pharmaceuticals in conjunction with basic peroral therapy and widely accepted discrete stepwise approach of the World Health Organization showed first positive results. In our opinion, further studies will allow to 1) decrease the rate of chronic pain syndrome in oncological patients; 2) treat pain syndrome of almost any intensity with preserved quality of life.The first results are encouraging; they show satisfactory effectiveness of the method and its safety. It is necessary to continue studies to develop and standardize the intravenous mixture composition for pain management in the context of the main clinical syndromes determining pain.

2 June 2022 in MD-Onco
Verified
Journal Article
Open access
PDF file
YRYu. E. Ryabukhina
Yu. E. Ryabukhina
PZP. A. Zeynalova
P. A. Zeynalova
VGV. E. Gruzdev
V. E. Gruzdev
MAM. A. Anisimov
M. A. Anisimov
AFA. A. Fedenko
A. A. Fedenko
ЮРЮ. Е. Рябухина
Ю. Е. Рябухина
Recently due to significant successes in drug therapy of malignant tumors, the question of quality of life of patients has become more important. Cyclical drug treatment implies intravenous infusion of antitumor agents. Complications associated with this type of therapy include phlebitis and extravasation and, in some cases, lead to full obliteration of vessel lumen and vast skin and hypoderm necrosis. Multiple venous punctions can with time lead to significant technical difficulties in accessing the vein and limit the continuation of therapy. This drives the necessity to search for rational approaches to patient safety during both outpatient and inpatient antitumor drug treatment. To solve this problem, fully implanted venous port systems were developed and implemented in clinical practice which provide organization of aseptic continuous venous access, as well as infusion pumps (for independent prolonged intravenous therapy). Use of these devices allows for continuity and cycling of treatment process, significantly improves patients' quality of life by not limiting daily activities.In the article we present our experience of using microinfusion single-use mechanical systems for antitumor drug therapy and relief of intense pain syndrome in patients with malignant disorders of hematopoietic tissue and solid tumors.

20 September 2023 in MD-Onco
Verified
Journal Article
Open access
PDF file
MDM. A. Dzhopua
M. A. Dzhopua
VGV. E. Gruzdev
V. E. Gruzdev
MAM. A. Anisimov
M. A. Anisimov
VGV. E. Gordobaev
V. E. Gordobaev
ATA. V. Tatarenko
A. V. Tatarenko
This paper describes the first experience of the department in using an electronic infusion pump in order to optimize and select an adequate and safe method of permanent analgesia in cardiac surgery patients in the perioperative period. Two clinical cases of using an infusion pump for continuous anesthesia are also presented.